Clinical Trial

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-19.
Trial Details
NCT Number NCT06564272
Lead Sponsor Beijing Konruns Pharmaceutical Co., Ltd.
Conditions Ewing Sarcoma
Enrollment 30 participants
Start Date 2024-09-27
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-23